Sune Holm

Sune Holm

Auto-generated profile, based on publicly available information

Sune Holm

Department of Food and Resource Economics, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
JAJulia Amann
Julia Amann
DVDennis Vetter
Dennis Vetter
SBStig Nikolaj Blomberg
Stig Nikolaj Blomberg
HCHelle Collatz Christensen
Helle Collatz Christensen
MCMegan Coffee
Megan Coffee
OIOn Behalf Of The Z-Inspection Initiative
On Behalf Of The Z-Inspection Initiative
Explainability for artificial intelligence (AI) in medicine is a hotly debated topic. Our paper presents a review of the key arguments in favor and against explainability for AI-powered Clinical Decision Support System (CDSS) applied to a concrete use case, namely an AI-powered CDSS currently used in the emergency call setting to identify patients with life-threatening cardiac arrest. More specifically, we performed a normative analysis using socio-technical scenarios to provide a nuanced account of the role of explainability for CDSSs for the concrete use case, allowing for abstractions to a more general level. Our analysis focused on three layers: technical considerations, human factors, and the designated system role in decision-making. Our findings suggest that whether explainability can provide added value to CDSS depends on several key questions: technical feasibility, the level of validation in case of explainable algorithms, the characteristics of the context in which the system is implemented, the designated role in the decision-making process, and the key user group(s). Thus, each CDSS will require an individualized assessment of explainability needs and we provide an example of how such an assessment could look like in practice.

29 July 2022 in IEEE Transactions on Technology and Society
Verified
Journal Article
Open access
HAHimanshi Allahabadi
Himanshi Allahabadi
JAJulia Amann
Julia Amann
IBIsabelle Balot
Isabelle Balot
ABAndrea Beretta
Andrea Beretta
CBCharles Binkley
Charles Binkley
RZRoberto V. Zicari
Roberto V. Zicari
The paper’s main contributions are twofold: to demonstrate how to apply the general European Union’s High-Level Expert Group’s (EU HLEG) guidelines for trustworthy AI in practice for the domain of healthcare; and to investigate the research question of what does “trustworthy AI” mean at the time of the COVID-19 pandemic. To this end, we present the results of a post-hoc self-assessment to evaluate the trustworthiness of an AI system for predicting a multi-regional score conveying the degree of lung compromise in COVID-19 patients, developed and verified by an interdisciplinary team with members from academia, public hospitals, and industry in time of pandemic. The AI system aims to help radiologists to estimate and communicate the severity of damage in a patient’s lung from Chest X-rays. It has been experimentally deployed in the radiology department of the ASST Spedali Civili clinic in Brescia (Italy) since December 2020 during pandemic time. The methodology we have applied for our post-hoc assessment, called Z-Inspection, uses socio-technical scenarios to identify ethical, technical and domain-specific issues in the use of the AI system in the context of the pandemic.

18 January 2018 in Journal of Law and the Biosciences
Verified
Journal Article
Open access
PDF file
ANAna Nordberg
Ana Nordberg
TMTimo Minssen
Timo Minssen
SHSune Holm
Sune Holm
MHMaja Horst
Maja Horst
Kell MortensenKell Mortensen
Kell Mortensen
BMBirger Lindbergi Møller
Birger Lindbergi Møller
Gene-editing technology, such as CRISPR/Cas9, holds great promise for the advancement of science and many useful applications technology. This foundational technology enables modification of the genetic structure of any living organisms with unprecedented precision. Yet, in order to enhance its potential for societal benefit, it is necessary to adapt rules and produce adequate regulations. This requires an interdisciplinary effort in legal thinking. Any legislative initiative needs to consider both the benefits and the problematic aspects of gene editing, from a broader societal and value-based perspective. This paper stems from an interdisciplinary research project seeking to identify and discuss some of the most pressing legal implications of gene-editing technology and how to address these. While the questions raised by gene editing are global, laws and regulations are to a great extent bound by national borders. This paper presents a European perspective, written for a global audience, and intends to contribute to the global debate. The analysis will include brief references to corresponding USA rules in order to place these European debates in the broader international context. Our legal analysis incorporates interdisciplinary contributes concerning the scientific state of the art, philosophical thinking regarding the precautionary principle and dual-use issues as well as the importance of communication, social perception, and public debate. Focusing mainly in the main regulatory and patent law issues, we will argue that (a) general moratoriums and blank prohibitions do a disservice to science and innovation; (b) it is crucial to carefully consider a complex body of international and European fundamental rights norms applicable to gene editing; (c) these require further developments grounded in consistent and coherent implementation and interpretation; (d) legal development should follow a critical contextual approach capable of integrating interdisciplinary contributions and broad multilevel societal dialog.

21 February 2022 in Res Publica
Verified
Journal Article
Closed access
PDF file
SHSune Holm
Sune Holm

12 June 2023
Verified
Conference Paper
Open access
EPEike Petersen
Eike Petersen
MGMelanie Ganz
Melanie Ganz
SHSune Holm
Sune Holm
AFAasa Feragen
Aasa Feragen
Recent work on algorithmic fairness has largely focused on the fairness of discrete decisions, or classifications. While such decisions are often based on risk score models, the fairness of the risk models themselves has received considerably less attention. Risk models are of interest for a number of reasons, including the fact that they communicate uncertainty about the potential outcomes to users, thus representing a way to enable meaningful human oversight. Here, we address fairness desiderata for risk score models. We identify the provision of similar epistemic value to different groups as a key desideratum for risk score fairness, and we show how even fair risk scores can lead to unfair risk-based rankings. Further, we address how to assess the fairness of risk score models quantitatively, including a discussion of metric choices and meaningful statistical comparisons between groups. In this context, we also introduce a novel calibration error metric that is less sample size-biased than previously proposed metrics, enabling meaningful comparisons between groups of different sizes. We illustrate our methodology – which is widely applicable in many other settings – in two case studies, one in recidivism risk prediction, and one in risk of major depressive disorder (MDD) prediction.

9 June 2023 in Cambridge Quarterly of Healthcare Ethics
Verified
Journal Article
Open access
PDF file
SHSune Holm
Sune Holm
When is it justified to use opaque artificial intelligence (AI) output in medical decision-making? Consideration of this question is of central importance for the responsible use of opaque machine learning (ML) models, which have been shown to produce accurate and reliable diagnoses, prognoses, and treatment suggestions in medicine. In this article, I discuss the merits of two answers to the question. According to the Explanation View, clinicians must have access to an explanation of why an output was produced. According to the Validation View, it is sufficient that the AI system has been validated using established standards for safety and reliability. I defend the Explanation View against two lines of criticism, and I argue that within the framework of evidence-based medicine mere validation seems insufficient for the use of AI output. I end by characterizing the epistemic responsibility of clinicians and point out how a mere AI output cannot in itself ground a practical conclusion about what to do.